

WEISS & MOY, P.C.

Reply to:
Mark H. Weiss
4204 N. Brown Avenue
Scottsdale, AZ 85251
(480) 994-8888 (t)
(480) 947-2663 (I)
mweiss coweissiplaw.com

March 31, 2016

OTC Markets Group, Inc.
304 Hudson Street, Second Floor
New York, NY 10013

Re: Attorney Letter for Global Profit Technologies, Inc.

Gentlemen:

We represent Global Profit Technologies, Inc., a Florida Corporation (the "Company"). The Company has requested that we review the disclosures made by the Company pursuant to Pink OTC Markets' Guidelines for Providing Adequate Current Information and that we submit this letter to Pink OTC Markets on its behalf. The undersigned is a United States resident, admitted to practice law in the State of Arizona and permitted to practice before the Securities and Exchange Commission (the "SEC"), has not been prohibited from practice before the SEC, and we are not currently under investigation by any federal or state regulatory authority. We are general counsel to the Company.

We have examined the following corporate records and other documents, including, those which have been made publicly available through the Company's posting of such documents to www.otcmarkets.com through the OTC Disclosure and News Service (the "Service") (collectively, hereinafter referred to as the "Information"):

1. Articles of Incorporation of Global Profit Teclmologies, inc. a copy of which was posted through the Service on February 13, 2009.

2. Bylaws of Global Profit Technologies, Inc., a copy of which was posted through the Service on February 25, 2009.

3. The Company's Initial Company Information and Disclosure Statement, a copy of which was posted through the Service on February 13, 2009.

4. The Company's unaudited financial statements for the twelve months ended December 31, 2015, consisting of:

(A) Condensed Consolidated Balance Sheets as of the end of each of the four fiscal quarters in 2015;

(B) Condensed Consolidated Statements of Operations for each of the four fiscal quarters in 2015;

(C) Condensed Consolidated Statement of Stockholders Deficit for each of the four fiscal quarters in 2015;

(D) Condensed Consolidated Statements of Cash Flows for each of the three fiscal quarters in 2015;

(E) Footnotes for each of the fiscal fiscal quarters in 2015; and

(F) Management's Discussion and Analysis of Financial Condition and Results of Operations for each of the four fiscal quarters in 2015.

all of which were posted through the Service on May 15, 2015, July 15, 2015, November 15, 2015, and March 31, 2016.

6. Board of Directors Resolutions dated October 7, 2011.

7. The Company's Annual Report for the fiscal year ending December 31, 2015 copy of which was posted through the Service on March 31, 2016.

The items referenced were prepared internally by management under the guidance of the Company's Chief Financial Officer, Brian Duling, who is an accountant, MBA, and chief financial officer with in excess of 25 years of experience in establishing and managing corporate financial controls.

The items referenced Section Two of the Pink OTC Markets Guidelines for Providing Adequate Current Information,

Item 5 — Legal Proceedings, N/A.

Item 6 — N/A.

Item 7 — N/A.

Item 8 — N/A.

The Company's transfer agent is Pacific Stock Transfer Company, which is registered with the SEC. We have confirmed the number of outstanding shares set forth in the Information by verbally confirming the number of outstanding shares with the Company's transfer agent and discussing with Joseph Nemeth, the Company's CEO and Chairman of the Board, President and CEO, a letter which he received from the Company's transfer agent which confirmed the number of the Company's outstanding shares.

We have also met with management and all of the directors of the Company through our personal meetings with Joseph Nemeth, Chairman of the Board and Brian Duling, Chief Financial Officer and a board

member. Mr. Duling confirmed that the Company USA operations are in a 'virtual office' manner, where there are no leased executive office facilities. The Company's CEO, Joseph Nemeth, utilizes office space from a residential office, located at 35840 N 61st Street, Carefree, AZ 85331. The Company incurs no expense for this residential office and there is no mortgage or other encumbrances on this location.

The Company maintains a non-leased facility in Slovakia, at the address of Krizovany, 919 24 Krizovany nad Dudvoham, Slovakia EU. The Company incurs no expense for this office and there is no mortgage or other encumbrances on this location. The Company's executive office mailing address is 9393 North 90th Street, Suite 102-344, Scottsdale, AZ 85258. The Company anticipates that when appropriate for business operational needs that it would have no difficulty in securing leased office facilities.

There has been no legal/disciplinary history with any of the officers of the Company. There is one beneficial owner of the Company, Joseph Nemeth. Mr. Nemeth's address is Krizovany, 919 24 Krizovany nad Dudvoham, Slovakia EU, with a USA business/mailing address of 9393 North 90th Street, Suite 102344, Scottsdale, AZ 85258.

For purposes of preparing this letter, we do not express any opinion with respect to the applicable laws, or the effect or applicability of the laws, or any jurisdiction other than those of the State of Arizona and the securities laws of the United States. As to matters of fact, we have relied upon information from Joseph Nemeth, Brian Duling and Michael Rabicoff which we believe to be reliable.

The Company's stock price on Pink Quote "is available" within the meaning of Rule 144(c)(2) promulgated pursuant to the Securities Act of 1933, (ii) includes all of the information which a broker-dealer would be required to obtain from the Company in order to publish a quotation for the securities pursuant to Rule 15c2-I I promulgated under the Securities Exchange Act of 1934, as amended, (iii) complies as to form with the Pink OTC Markets, Inc.'s Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otemarkets.com and (iv) has been posted through the OTC Disclosure and News Service. After inquiry of management and the directors of the Issuer, we have no knowledge that the Company or any of the Company's 5% or greater shareholders are currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

This letter may be relied upon by Pink OTC Markets, Inc. in determining whether the Company has made adequate current information publicly available within the meaning of Rule I 44(c)(2) under the Securities Act of 1933. This letter may not be relied upon by any other person or entity other than Pink OTC Markets, Inc. However, Pink OTC Markets, Inc. has full and complete permission and rights to publish this letter through the OTC Disclosure and News Service for viewing by the public and regulators.

This opinion speaks only as the date above written and is limited to laws and regulations now in effect, and in all respects is subject to any, and may be limited by, future legislation, regulatory pronouncements and case law. We hereby expressly disclaim any duty to update any of the statements made herein.

Very truly yours,

WEISS & MOY, P.C.



Mark Weiss